PepMix™BKV(capsidproteinVP1)ProductCode:PM-BKV-VP1Poolof88peptidesderivedfromapeptidescan(15merswith11aaoverlap)throughMajorcapsidproteinVP1(Swiss-ProtID:P14996)ofBKpolyomavirusforTcellassays(e.g.ELISPOT).Amount:1vialcontaining15nmol(appr.25µg)perpeptidePurity:>70%(HPLC-MS)DeliveryFormat:FreezedriedinambertypeglassvialApplication(s):T-cellassays,Immunemonitoring,AntigenspecificT-cellstimulation,T-cellexpansion,CellularimmuneresponseIndication(s)/Topic(s):Infection,AIDS,Cancerchemotherapy,Transplantation,Merkelcellcarcinoma,PMLandBKnephropathyDeliveryTime:2-5daysPepMix™PeptidePoolsTheuseofcompleteprotein-spanningmixturesofoverlappingpeptides(PepMix)isextremelyefficientforimmunostimulationofT-lymphocytesanddiagnosticapplications.InordertoestablishreliableandvalidatedT-cellassayssuchasELISPOT,appropriatepositiveandnegativecontrolsareessential.SelectionofsuchcontrolshelpstoconfirmproperfunctionalityoftheassayaswellasviABIlityofthecellsused.Inaddition,highqualitycontrolsaremostimportanttoestablishstandardizedassayprotocolsinclinicalsetups.Comparedtocommonlyusedcontrolslikephytohemagglutinin(PHA)andconcanavalinA(ConA)thatstimulateT-cellsaswellasothercelltypesorfulllengthantigens,syntheticpeptidepoolsoffertheadvantageofahighbatch-to-batchreproducibility,applicabilityofreliablechemicalandbiochemicalQC/QAmeasuresandshelfstabilitywhenstoredasfreezedriedaliquots.BenefitsofPepMix™PeptidePools-EquivalentorbetterstimulationofCD4+andCD8+antigen-specificT-cellresponsescomparedtowholeproteinantigens-SimultaneousdetectionofCD4+andCD8+responsesinasinglesample-ImprovedresponsesinstoredbloodandPBMcellscomparedtowholeproteinantigensPepMix™BKV(capsidproteinVP1)SelectedReferences"InVitroStudiesoftheImpactofMaribavironCMV-SpecificCellularImmuneResponses"Stacheletal.,JClinVirol. (2015)-PMID:26780109"InductionOfBroad-basedImmunityandProtectiveEfficacybySelf-amplifyingmRNAVaccinesEncodingInfluenzaVirusHemagglutinin"Brazzolietal.,JournalofVirology (2015)-PMID:26468547"TargetingofNucleoproteintoChemokineReceptorsbyDNAVaccinationResultsinIncreasedCD8+-mediatedCrossProtectionAgainstInfluenza"Baranowskaetal.,Vaccine(2015)-PMID:26387432"CharacteristicsofImmuneMemory10-15yearsAfterPrimaryHepatitisBVaccination"Hummeletal.,Vaccine(2015)-PMID:n.a."TCellsSpecificforDifferentLatentandLyticViralProteinsEfficientlyControlEpstein-BarrVirusTransformedBCells"Nowakowskaetal.,Cytotherapy(2015)-PMID:26276009"High-densityPrecultureofPBMCsRestoresDefectiveSensitivityofCirculatingCD8TCellstoVirus-andTumor-derivedAntigens"Wegneretal.,Blood(2015)-PMID:26024876"MetabolicRegulationofHepatitisBImmunopathologybyMyeloid-derivedSuppressorCells"Pallettetal.,NatureMedicine(2015)-PMID:25962123ApplicationNotes"DevelopingMulti-HIVAntigenSpecificT-CellsasaComponentofaCureStrategy"Lametal.(2015)Fulltext"Peptide-stimulatedExpansionofVirus-specificTcellsForPreventativeTreatmentAfterAllogeneicStemCellTransplantation"Garyetal.(2015)FulltextTestimonials"Toestablishanovelroleformyeloidderivedsuppressorcells(Pallettetal,Nat.Med.2015)inchronicviralinfection,weutilisedthePepMixCEFPool(extended)aswellasacustomsynthesizedPepMixspanningthecoreregionofHBVgenotypeD.Whereas,theCEFpeptidepoolconsistsof32peptides,eachcorrespondingtoadefinedHLAclassI-restrictedT-cellepitopefromCytomegalo,Epstein-Barr,andInfluenzavirus,thelattercustomPepMixincluded15mericpeptidesoverlappingby10aminoacids.SpecificallythiscompositionenabledustomonitorboththeantiviralCD8+andCD4+TcellresponsesinchronicHBVinfectionandthenon-antigenspecificTcellsthatareknowntomediateimmunopathologyintheliver.OurentireexperiencewithJPT,fromordering/deliverytouseinthelabwasexcellent.Notonlywerethereagentsabletoperformreliablyandconsistentlyinvitrofrombatchtobatch,thecustomerandtechnicalsupportprovidedwascontinuallyavailableandefficientwhenneeded.JPTwillremainour"go-to"companyforpurchasingpeptides."Dr.LauraJPallett,InfectionandImmunity,UniversityCollegeLondon,UKPepMix™BKV(capsidproteinVP1)TechnicalData:ApplicationAntigenspecificT-cellstimulationImmunemonitoringT-cellassaysT-cellexpansionProteinNameMajorcapsidproteinVP1OrganismBKpolyomavirusIndication/TopicMerkelcellcarcinomaNumberofpeptides88 FurtherInformation:Amount1vialcontaining15nmol(appr.25µg)perpeptideSpecificationsPeptidescan(15merswith11aaoverlap)DocumentationProtocolandDatasheetSwiss-ProtIDP14996NCBIYP_717939SequenceMAPTKRKGECPGAAPKKPKEPVQVPKLLIKGGVEVLEVKTGVDAITEVECFLNPEMGDPDDNLRGYSQHLSAENAFESDSPDRKMLPCYSTARIPLPNLNEDLTCGNLLMWEAVTVKTEVIGITSMLNLHAGSQKVHENGGGKPVQGSNFHFFAVGGDPLEMQGVLMNYRTKYPQGTITPKNPTAQSQVMNTDHKAYLDKNNAYPVECWIPDPSRNENTRYFGTYTGGENVPPVLHVTNTATTVLLDEQGVGPLCKADSLYVSAADICGLFTNSSGTQQWRGLARYFKIRLRKRSVKNPYPISFLLSDLINRRTQKVDGQPMYGMESQVEEVRVFDGTEQLPGDPDMIRYIDRQGQLQTKMVProteinLength(aa)362